prism® 2005 version 4.03 (GraphPad Software Inc)
90
Structured Review
GraphPad Software Inc
prism® 2005 version 4.03
Prism® 2005 Version 4.03, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prism%C2%AE+2005+version+4%2E03/prism+software/pm20018492-98-21-25
Average 90 stars, based on 1 article reviews
Prism® 2005 Version 4.03, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prism%C2%AE+2005+version+4%2E03/prism+software/pm20018492-98-21-25
Average 90 stars, based on 1 article reviews
prism® 2005 version 4.03 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Article Snippet: The objectives of this study were (i) to compare the plasma concentration–time profiles for first-dose and steady-state piperacillin administered by intermittent or continuous dosing to critically ill patients with sepsis and (ii) to use population pharmacokinetics to perform Monte Carlo dosing simulations in order to assess the probability of target attainment (PTA) by minimum inhibitory concentration (MIC) for different piperacillin dosing regimens against bacterial pathogens commonly encountered in critical care units.. Plasma samples were collected on Days 1 and 2 of therapy in 16 critically ill patients, with 8 patients receiving intermittent bolus dosing and 8 patients receiving continuous infusion of piperacillin (administered with tazobactam).. A population pharmacokinetic model was developed using NONMEM®, which found that a two-compartment population pharmacokinetic model best described the data. |